Antibodies News and Research

RSS

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

In a recent study, scientists have quantified anti-SARS-CoV-2 antibody levels up to 9 months after infection.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

COVID-19 antibodies can protect against reinfection for at least eight months

A new study offers hope that recovered patients from COVID-19 are largely immune to reinfection for at least eight months.

23 Mar 2021

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.

23 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.

From FairJourney Biologics 23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

Simple SARS-CoV-2 mutations allow escape from the majority of polyclonal antibodies

The group identified a single class of antibodies that target a particular epitope on the RBD of SARS-CoV-2, suggesting that the human polyclonal response to SARS-CoV-2 infection is dominated by a worryingly narrow range of antibodies that target an epitope undergoing rapid mutation.

22 Mar 2021

Most cancer patients with COVID-19 produce antibodies at a rate comparable to general population

Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population--but their ability to do so depends on their type of cancer and the treatments they've received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of Medicine.

22 Mar 2021

New method could drive down the production cost of antibodies

Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn's disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.

22 Mar 2021

YAP inhibitors could facilitate targeted treatment of basal-like breast cancer

Targeted treatment of basal-like breast cancer could be facilitated by YAP inhibitors in the future. As reported by an MDC team headed by Walter Birchmeier in the scientific journal Cancer Research, this type of cancer requires the support of the YAP protein to stimulate the growth of cancer stem cells.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

Researchers develop new method for measuring immunity to coronavirus

Igor Stagljar made his career building molecular tools to combat cancer. But when the pandemic hit last March, he aimed his expertise at a new adversary, SARS-CoV-2.

22 Mar 2021

Can SARS-CoV-2 still be transmissible once symptoms have subsided?

Researchers based at the University of Missouri, in partnership with U.S. government science facilities in Maryland, have reported that individuals severely infected with SARS-CoV-2 may be able to continue shedding infectious viral RNA for over three weeks after the symptomatic infection has passed.

22 Mar 2021

Prediction of antibody responses in recovered COVID-19 patients remains unclear

It is crucial to gain a better understanding of how an antibody response is developed against SARS-CoV-2, and how long it lasts. This will determine the antibody titers and duration that protect against reinfection by the virus. A new preprint on the medRxiv* server shows this to be still a distant goal.

22 Mar 2021

Male fertility and androgen production may be impacted by COVID-19

An interesting new study has appeared online in the journal Hormones that discusses the effects of COVID-19 on the male and female gonads.

22 Mar 2021

The hype has faded, but don’t count out convalescent plasma in Covid battle

Six months after it was controversially hailed by Trump administration officials as a "breakthrough" therapy to fight the worst effects of Covid-19, convalescent plasma appears to be on the ropes.

22 Mar 2021

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

To understand the ability of SARS-CoV-2 vaccine-elicited antibodies to neutralize and protect against emerging variants (that are pathogenic) and other sarbecoviruses, a large team of researchers studied immunity by receptor-binding domain nanoparticle vaccines. They showed that a clinical-stage multivalent SARS-CoV-2 receptor-binding domain nanoparticle vaccine (SARS-CoV-2 RBD-NP) protected mice from the SARS-CoV-2-induced disease.

22 Mar 2021

Blocking folate metabolism could reduce SARS-CoV-2 viral replication in infected cells

The novel beta-coronavirus virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and coronaviruses, in general, alter the host's cellular metabolism to support massive production of ~30 kB viral genomes and subgenomic viral RNAs. However, how this is achieved is largely unknown.

21 Mar 2021

Circular RNA vaccine shows neutralizing activity against B.1.351 variant

New preclinical research led by Wensheng Wei from Peking University in China has proposed the development of a circular RNA vaccine. Their findings showed the circular RNA vaccine creates neutralizing antibodies and strong T-cell responses against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

21 Mar 2021